Drugs / insulin degludec/insulin aspart
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06199505 Comparator | Nov 2023 → Jun 2024 | type 2 diabetes mellitus | Gan and Lee Pharmaceuticals, USA | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | insulin degludec/insulin aspart | “insulin degludec/insulin aspart injection s.c., once or twice daily, treat-to-target dose” NCT06199505 ↗ |
| Route | Subcutaneous | “insulin degludec/insulin aspart injection s.c., once or twice daily, treat-to-target dose” NCT06199505 ↗ |